The latest ESC 2021 guidelines on the treatment of heart failure with reduced ejection fraction recommend the introduction of therapy with ARNI and SGLT2 inhibitors as first-line treatment in patients with HFrEF, along with beta-blockers and potassium-sparing diuretics, with a Class I, Level of Evidence A recommendation [12]. This evidence concerns the gene SLC5A2 and heart failure.